The tweet was deleted by the author.
But we saved everything 🙂.
Haemonetics marks U.S. launch of PerQseal Elite after stock ends session down 3.3%
Haemonetics marked an important milestone with the U.S. commercial launch of its PerQseal Elite Vascular Closure System. Shares are down 3.3% on the day at $119.93.
Highlights
- Haemonetics began U.S. commercialization of its PerQseal Elite Vascular Closure System, a patch-based large-bore closure device.
- Shares of Haemonetics are down 3.3% on the day at $119.93.
- 34 of 44 analysts rate Haemonetics stock a buy, with a median price target of $127.5.
Haemonetics marked the U.S. commercial launch of the PerQseal Elite Vascular Closure System. The PerQseal Elite is a patch-based large-bore closure technology. The announcement was made at TCT 2026.
View post on X Loading...
Split daily structure as price holds between key moving averages
Price is sitting right at resistance from MA-20 at $120.1. Shares of Haemonetics are trading below the MA-20 but above the MA-50 and MA-200, which creates a split daily structure. Stoch RSI is in oversold territory, suggesting the downside is limited and may support stabilization at current levels.
Upside odds strengthen as traders await a close above resistance
To gauge whether sentiment is shifting, traders should look for a close above $120.1 as evidence that buyers are following through. The session opened with a gap down from the previous close of $124.07 to $121.16, highlighting defensive action early in the day. Even so, from here the upside probability over the next five trading days is 62%, while the downside probability is 38%, and the expected range is $114.13 to $125.72. A drop below $117.2 would indicate the move is being faded. On the weekly chart, the longer-term picture stays firmly constructive.
Previously it was reported that Haemonetics maintained a broadly bullish technical setup supported by recent earnings momentum. The current mixed technical structure and reaction to the PerQseal Elite launch add a new dimension, with traders advised to monitor the $120.1 level for signs of near-term stabilization or further downside risk.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Latest Haemonetics News
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
